Skip to main content
. 2020 Nov 10;11(11):963. doi: 10.1038/s41419-020-03172-8

Fig. 4. UBP310 decreases the level of the GluK2 subunit of KAR.

Fig. 4

a Representative Western blots showing GluK2 immunostaining from total brain lysates obtained from WT or parkinQ311X mice treated with 20 mg/kg UBP310 i.p. for either 4 or 8 h. The graphs show the means ± SEM from densitometer quantifications (WT—white bars, Q311X—gray bars). UBP310 treatment induced a decrease in GluK2 levels. WT mice, NT 1.00 ± 0.02, 4 h 0.77 ± 0.03, 8 h 0.71 ± 0.08, 4 h vs. NT *p = 0.047, 8 h vs. NT *p = 0.0011, F = 7.276, one-way ANOVA with Bonferroni’s test. ParkinQ311X mice, NT 1.00 ± 0.05, 4 h 0.92 ± 0.04, 8 h 0.73 ± 0.02, 8 h vs. NT **p = 0.0013, F = 13.36, one-way ANOVA with Bonferroni’s test. UBP310 did not change the levels of AMPA receptor subunits GluA1 and GluA2. b Representative confocal images showing TH (red) and GluK2 (green) double immunofluorescence in the SNc of WT or parkinQ311X mice treated with either vehicle or 20 mg/kg UBP310 i.p. for 8 h. Images were acquired using a Leica TCS SP2 confocal microscope, objective 40× (bar, 50 µm). The histograms show the means ± SEM from fluorescence-intensity quantifications. Twelve sections per genotype/treatment were examined derived from n = 3 WT mice treated with vehicle, n = 3 WT mice treated with UBP310, n = 3 parkinQ311X mice treated with vehicle, and n = 3 parkinQ311X mice treated with UBP310. GluK2/TH: WT vehicle 1.00 ± 0.08 n = 95 neurons, WT UBP310 0.7 ± 0.09 n = 91 neurons, parkinQ311X vehicle 1.67 ± 0.08 n = 102 neurons, parkinQ311X UBP310 1.25 ± 0.07 n = 100 neurons, WT vehicle vs. WT UBP310 *p = 0.039, Q311X vehicle vs. Q311X UBP310 p = 0.0006, WT vehicle vs. Q311X vehicle p = 0.00009, F = 27.95, one-way ANOVA followed by Tukey’s test.